Skip to main content
Clinical Trials/NCT05177562
NCT05177562
Recruiting
Not Applicable

Reproductive Endocrinology Oxford Study (RepOx)

University of Oxford1 site in 1 country1,175 target enrollmentOctober 21, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Polycystic Ovary Syndrome
Sponsor
University of Oxford
Enrollment
1175
Locations
1
Primary Endpoint
Identify the underlying genetic and pathophysiological mechanisms of PCOS and associated phenotypes
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

This is a prospective observational study that aims to identify the underlying mechanisms of PolyCystic Ovarian Syndrome (PCOS) and associated comorbidities such as subfertility, miscarriage; and pregnancy complications such as gestational diabetes mellitus and Intrahepatic cholestasis of pregnancy (ICP). This will be achieved through cross-sectional observation and laboratory analyses.

Detailed Description

Here we propose a comprehensive program to dissect the underlying disease-causing mechanisms of PCOS and associated comorbidities. We will investigate how the different layers of biological information (ranging from DNA variant genotyping, to RNA sequencing and proteomics), and clinical characteristics are correlated with each other and how this affects PCOS in fat tissue derived cells, as well as ovarian tissue and tissue derived cells by using a combination of big data analysis, a range of "-omics" technologies, of both in-house generated and publicly available data, paired with state of the art statistical and bioinformatics analysis. Out of these mechanisms and pathways we will identify druggable targets for proposals for detailed functional follow up with an aim of development of novel therapeutic options for PCOS.

Registry
clinicaltrials.gov
Start Date
October 21, 2021
End Date
September 1, 2028
Last Updated
4 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ● General Criteria for all groups
  • Participant is willing and able to give informed consent for participation in the study.
  • Female, aged between 16 and 45 years of age. As IVF is not undertaken in women less that 18 years, this group will between 18 and 45 years o
  • ● PCOS (Group 1, 2 and 3)
  • Currently under investigation for or having diagnosis of PCOS having displayed one or more of the following: Hyperandrogenism, Ovulation Dysfunction and Polycystic ovaries on ultrasound (known as the Rotterdam criteria)
  • ● PCOS Controls (Group 4 and 5)
  • Patients under gynaecological investigation or having assisted reproduction
  • Exhibit no features of PCOS
  • ● Miscarriage Group (Group 6)
  • Have had at least two previous miscarriages

Exclusion Criteria

  • For all groups - The participant may not enter the study if ANY of the following apply.
  • Unable to read, or to understand written or spoken English
  • Currently involved in any Clinical Trial of an Investigational Medicinal Product (CTIMP)
  • Undergoing surgery because of a possible cancer diagnosis
  • Diagnosis of other androgen excess disorders such as Congenital Adrenal Hyperplasia (CAH), Androgen Secreting tumours, Cushing syndrome, or Hyperprolactinemia

Outcomes

Primary Outcomes

Identify the underlying genetic and pathophysiological mechanisms of PCOS and associated phenotypes

Time Frame: one visit

Questionnaire data, imaging analysis, medical records and sample analysis

Secondary Outcomes

  • To identify novel biomarkers of PCOS and associated comorbidities.(one visit)
  • To identify clinical subgroups of PCOS and associated comorbidities.(one visit)
  • To understand the genetics underlying these conditions and explore the relevant downstream molecular pathways(one visit)
  • To identify novel drug targets, develop models of disease progression and prediction.(one visit)

Study Sites (1)

Loading locations...

Similar Trials